Druker Brian 4

What Happened
Brian Druker, a director of Amgen Inc. (AMGN), was granted/received 665 restricted stock units (RSUs) on 2026-05-19. The filing shows an acquisition at $0.00 (award), meaning these were compensation awards rather than cash purchases. The RSUs vested immediately and are payable one-for-one in Amgen common stock; the filing reports the award value as $0.

Key Details

• Transaction date: 2026-05-19; Form 4 filed 2026-05-21 (timely filing).
• Transaction type/code: A (award/grant/acquisition); price reported $0.00.
• Shares acquired: 665 RSUs (total).
• Of the 665, 408 are dividend equivalents (DEs) credited to unvested RSUs under the plan (see footnote).
• Vested RSUs are paid in shares on a one-to-one basis and may be deferred by the director per an elected deferral schedule.
• Shares owned after the transaction: not specified in the provided excerpt.
• This appears to be routine director compensation, not an open-market purchase or sale.

Context

• RSU awards to directors are common as part of board compensation; they don’t necessarily signal a personal market view.
• Dividend equivalents (DEs) are additional credits tied to dividends that are ultimately paid out as shares per the RSU terms.
• Because the award vested immediately, Druker will receive (or has received) shares unless he elected to defer payment under Amgen’s deferral rules.